A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp

Clinical Microbiology and Infection

Volumn 14, Issue 6, 2008, Pages 608-611

  Drago, Lorenzo ^a   Nicola, L ^a   De Vecchi, E ^a  

^a DISP LITA Vialba   (Italy)

Author keywords

Enterococci; Glycopeptides; Linezolid; Quinupristin dalfopristin; Resistance selection; Staphylococcus aureus

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DRUG EXPOSURE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 43149103399     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01993.x     Document Type: Article

References (20)

1. M Khare D Keady Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection Expert Opin Pharmacother 4 2003 165 177
2. P Apfalter MRSA/MRSE-VISA/GISA/VRSA-PRP-VRE: current gram positive problem bacteria and mechanism of resistance, prevalence and clinical consequences Wien Med Wochenschr 153 2003 144 147
3. RS Evans JF Lloyd RH Abouzelof CW Taylor VR Anderson MH Samore System-wide surveillance for clinical encounters by patients previously identified with MRSA and VRE Medinfo 11 2004 212 216
4. K Hiramatsu H Hanaki T Ino K Yabuta T Oguri FC Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135 136
5. Anonymous First US case of vancomycin resistant Staphylococcus aureus infection reported in a patient with chronic renal failure Dial Transplant 31 2002 602 603
6. N El Solh M Davi A Morvan Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides J Antimicrob Chemother 52 2003 691 694
7. MG Bonora M Solbiati E Stepan Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage J Clin Microbiol 44 2006 1153 1155
8. BS Burleson DJ Ritchie ST Micek WM Dunne Enterococcus faecalis resistant to linezolid: case series and review of the literature Pharmacotherapy 24 2004 1225 1231
9. B Malbruny A Canu B Bozdogan Resistance to quinupristin–dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus Antimicrob Agents Chemother 46 2002 2200 2207
10. Clinical and Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing , 15th informational supplement, M100-S15 2005 CLSI Wayne, PA
11. P Chevalier J Rey O Pasquier R Rouzier-Panis N Harding G Montay Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers J Clin Pharmacol 41 2001 404 414
12. DP Healy RE Polk ML Garson DT Rock TJ Comstock Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers Antimicrob Agents Chemother 31 1987 393 397
13. DJ Stalker GL Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140
14. APR Wilson Clinical pharmacokinetics of teicoplanin Clin Pharmacokinet 39 2000 167 183
15. M MichéGa Hamzehpour A Kahr JC PechéGre In vitro stepwise selection of resistance to quinolones, β-lactams and amikacin in nosocomial Gram-negative bacilli Infection 22 suppl 2 1994 S105 S110
16. E De Vecchi L Nicola E Zucchetti L Drago In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes J Chemother 18 2006 379 388
17. SK Olofsson O Cars Optimizing drug exposure to minimize selection of antibiotic resistance Clin Infect Dis 45 2007 S129 S136
18. N McCallum H Karauzum R Getzmann In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance Antimicrob Agents Chemother 50 2006 2352 2360
19. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing , 16th informational supplement, M100-S16 2006 CLSI Wayne, PA
20. BA Cunha Principles of antimicrobial formulary selection for P&T Committees. Part 2: Pharmacokinetics and pharmacodynamics P&T 28 2003 468 470